why choose us

First received: January 23, 2023

Clinical Trial: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Cholangiocarcinoma

Study Type: INTERVENTIONAL


Official Title: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements

Brief Summary: This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.

Read more